7
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6033 |
Zotarolimus
ABT-578,佐他莫司,咗他莫司,A 179578 |
mTOR | PI3K/Akt/mTOR signaling |
Zotarolimus (ABT-578) 是一种免疫抑制剂,是雷帕霉素的衍生物,具有抗增殖活性。它被专门开发作为局部输送支架用于预防冠状动脉再狭窄。 | |||
T8687 |
diaminohydroxypropanetetraacetic acid
|
Others | Others |
diaminohydroxypropanetetraacetic acid 已被研究用于治疗血管疾病、冠状动脉疾病、心肌缺血、冠状动脉再狭窄和冠状动脉疾病等。 | |||
T24873 |
TGX-115
TGX 115 |
PI3K | PI3K/Akt/mTOR signaling |
TGX-115是一种细胞渗透性和有效的PI 3-K 异构体p110β/p110δ抑制剂(对p110β IC50值为 0.13 μM, 对p110δ值为0.63 μM),是一种调节血小板粘附过程的酶,可抑制磷酸肌苷(PI)3-激酶,可用来治疗冠状动脉闭塞、中风、急性冠状动脉综合征、急性心肌梗塞、血管再狭窄、动脉硬化和不稳定心绞痛等心血管疾病 。 | |||
T15696 |
NEP-IN-2
|
Others | Others |
NEP-IN-2 is an inhibitor of neutral endopeptidase. It also is used in the research of proliferation in atherosclerosis, restenosis. | |||
T68639 |
Ciprostene (free base)
|
||
Ciprostene (free base) is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty. | |||
T64285 | Protease-Activated Receptor-1 antagonist 2 | ||
Protease-Activated Receptor-1 antagonist 2 是一种选择性的、口服具有活力的蛋白酶激活受体-1 (PAR-1) 拮抗剂 (IC50: 7 nM)。Protease-Activated Receptor-1 antagonist 2 显示出良好的药代动力学特性,能够用于进行心血管疾病 (CVD) 的相关研究(如动脉粥样硬化和再狭窄)。 | |||
T74266 |
Protease-Activated Receptor-1 antagonist 2
|
||
Protease-Activated Receptor-1 antagonist 2 是一种选择性蛋白酶激活受体-1 (PAR-1) 拮抗剂,口服活性,IC50值为7 nM。该化合物具有优良的药代动力学特性,适用于心血管疾病 (CVD) 如动脉粥样硬化和再狭窄的研究。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6S0655 |
Corynoxeine
|
ERK | MAPK |
Corynoxeine 是从钩藤中分离的一种天然产物,是 PDGF-BB 诱导血管平滑肌细胞 (VSMCs) 增殖过程中的 ERK1/ERK2抑制剂。 |